Can @entity1486 levels predict bone scan evidence of @entity3 in newly diagnosed XXXX ?

@entity1 @entity263 @entity5 @entity3 @entity1486
Staging in @entity263 , as in any other @entity5 has significant ramifications in management. Currently, @entity1486 ( @entity1486 ) determination and the bone scan are two important procedures in the pretreatment staging workup of @entity263 . @entity1486 is a very useful serum tumor marker in the management of @entity263 @entity1 . We retrospectively evaluated 90 @entity1 at the time of initial diagnosis of @entity263 , all of whom had initial @entity1486 levels measured, as well as bone scans obtained. In addition to the @entity1486 level, we considered clinical stage and pathologic grade in the prediction of bone scan for @entity3 , at the time of initial diagnosis of @entity263 . Negative predictive value for @entity1486 values < 10 ng/ml (27 @entity1 ), clinical stage A (9 @entity1 ) and pathologic grade 1 (19 @entity1 ) was 100%. The number of @entity1 with bone scan evidence of @entity3 with < 10 ng/ml and > 10 ng/ml @entity1486 levels were 0% (0/27 @entity1 ) and 27% (17/63 @entity1 ) (p = .0022 [Fisher's Exact test]; p = .003 [chi-square test]). In @entity1 with higher stage (p = .688), grade (p = .039), or @entity1486 levels (p = .0001), the incidence of bone @entity3 increased. However, none of these three parameters can predict reliably bone scan evidence of @entity3 (i.e., positive predictive value). The negative predictive values did not improve when a combination of the two or three of the above parameters were used.
